Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07168564 · ClinicalTrials.gov registry record · NA
Post Marketing Clinical Study on the Efficacy of Lenses From a New Prescription Protocol
A NA study of Ametropia and Refractive Error, sponsored by Essilor International.
- Recruiting
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT07168564: Recruiting NA study of Ametropia and Refractive Error, sponsored by Essilor International.
NCT07168564 is a NA study of Ametropia and Refractive Error that is actively recruiting participants, run by Essilor International. The registered enrollment target is 120 participants, roughly in line with the 131-participant average among 5 other Ametropia trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07168564, a NA study of Ametropia and Refractive Error, is actively recruiting participants, sponsored by Essilor International.
- RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to assess improvements in visual performance and patient outcomes in wearing new spectacle lenses in general population. The two spectacle lenses will be compared after two weeks of wearing. The aims are: * to evaluate the visual superiority, and quality-of-life implications of Essilor® AVA™ spectacle lenses prescribed after a new subjective refraction protocol named AVA™ protocol. * to understand the benefits of using a high accuracy instrument and testing sequence over the standard testing sequence in determining a glasses prescription, as well as the overall subjective performance of the resulting glasses.
Primary Outcome
Proportion of subjects preferring vision correction option between Essilor® AVA™ lenses and the alternative vision correction solution
Conditions Studied
Interventions
- DEVICE AVA lenses
- DEVICE Standard lenses
Study Locations (1)
Indiana
- Clinical Optics Research Lab @ Borish Center for Ophthalmic Research Indiana University School of Optometry Indiana University - Bloomington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-09-22 |
| Est. Completion | 2026-01 |
| Phase | NA |
What NCT07168564 shows while recruiting
NCT07168564 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 131-participant average among 5 other Ametropia trials with a reported enrollment target.
The record links to 2 conditions, with Ametropia appearing as the primary indexed condition, and to 2 interventions - of which AVA lenses is the first listed.
NCT07168564 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT07168564 about?
NCT07168564 is a clinical study titled "Post Marketing Clinical Study on the Efficacy of Lenses From a New Prescription Protocol". The goal of this clinical trial is to assess improvements in visual performance and patient outcomes in wearing new spectacle lenses in general population. The two spectacle lenses will be compared after two weeks of wearing. The aims are: * to evaluate the visual superiority, and quality-of-life...
What is the current status of trial NCT07168564?
This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2025-09-22. Estimated completion is 2026-01.
What conditions does trial NCT07168564 study?
This clinical trial studies the following conditions: Ametropia, Refractive Error.
What interventions are being tested in trial NCT07168564?
The interventions under investigation include: AVA lenses (DEVICE), Standard lenses (DEVICE).
Who is sponsoring clinical trial NCT07168564?
This trial is sponsored by Essilor International, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07168564 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ametropia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clinical Performance of Two Commercial, Daily Disposable Contact Lenses
COMPLETED · NA
-
Apioc Contact Lens Feasibility
COMPLETED · NA
-
Evaluation of Monthly Replacement Lenses in Habitual Soft Contact Lens Wearers Who Report Frequent Digital Devise Use
COMPLETED · NA
-
North American Comfilcon A Clinical Study
RECRUITING
-
Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI